19 Promis Title - 25 Jul 2025 Form 4 Insider Report for ProMIS Neurosciences Inc. (PMN)

Role: 10%+ Owner
Signature: Title 19 Promis By: /s/ Michael S. Gordon, Manager
Issuer symbol: PMN
Transactions as of: 25 Jul 2025
Net transactions value: $0
Form type: 4
Filing time: 29 Jul 2025, 20:18:49 UTC
Previous filing: 02 Aug 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Title 19 Promis	10%+ Owner	C/O TROVE,, 40 BROAD STREET, 8TH FLOOR, BOSTON	Title 19 Promis By: /s/ Michael S. Gordon, Manager	29 Jul 2025	0002005531

This filing has been restated, see here for the amended filing

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PMN	Common Shares, no par value	Exercise of in-the-money or at-the-money derivative security		+119,800	+5.8%		2,195,429	25 Jul 2025	Direct	F1
transaction	PMN	Common Shares, no par value	Exercise of in-the-money or at-the-money derivative security		+119,800	+5.5%		2,315,229	25 Jul 2025	Direct	F2
transaction	PMN	Common Shares, no par value	Exercise of in-the-money or at-the-money derivative security		+119,800	+5.2%		2,435,029	25 Jul 2025	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PMN	Tranche A Common Share Purchase Warrants	Exercise of in-the-money or at-the-money derivative security	$0	-119,800	-26%	$0.000000	345,316	25 Jul 2025	Common Shares	119,800		Direct	F1
transaction	PMN	Tranche B Common Share Purchase Warrants	Exercise of in-the-money or at-the-money derivative security	$0	-119,800	-26%	$0.000000	345,316	25 Jul 2025	Common Shares	119,800		Direct	F2
transaction	PMN	Tranche C Common Share Purchase Warrants	Exercise of in-the-money or at-the-money derivative security	$0	-119,800	-26%	$0.000000	345,316	25 Jul 2025	Common Shares	119,800		Direct	F3
transaction	PMN	Warrants to Purchase Common Shares	Purchase		+539,100			539,100	29 Jul 2025	Common Shares	539,100		Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.
F2	On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.
F3	On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.
F4	On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance.